AVROBIO Inc. (AVRO) Prices 5M Share Common Offering at $15/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
AVROBIO Announces Pricing of Underwritten Public Offering of $75 Million of Common Stock
November 19, 2020 10:06 PM ESTCAMBRIDGE, Mass.--(BUSINESS WIRE)-- AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share. Gross proceeds from the underwritten public offering will total approximately $75 million, before deducting underwriting discounts and commissions and other offering expenses payable by the company. In addition, the company has granted the underwriters a 30-day option to purchase up to 750,000 additional shares of its common stock at the public offering price, less underwriting... More



